Summary:
- Astellas Pharma has initiated a Phase 3 clinical trial for setidegrasib, an investigational therapy targeting KRAS G12D-mutated advanced non-small cell lung cancer (NSCLC).
- The study evaluates the efficacy and safety of the drug in patients who have previously undergone treatment, representing a significant scientific effort to address a specific, difficult-to-treat genetic mutation in oncology.